文献速递肝病消化道出血

食管静脉曲张出血一级预防治疗的比较:系统评价与网状Meta分析

Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis.
PubMed 文献 · Hepatology · 2019-02-20

该系统评价与网状Meta分析纳入32项随机临床试验、共3362例肝硬化伴大食管静脉曲张且无出血史成人,比较非选择性β受体阻滞剂、硝酸异山梨酯、卡维地洛、曲张静脉套扎单独或联合及安慰剂的一级预防效果。中等质量证据支持非选择性β受体阻滞剂单药可能降低全因死亡,且严重不良事件风险低于套扎;作者认为非选择性β受体阻滞剂可能是首选初始方案。

要点

  • 中等质量证据支持非选择性β受体阻滞剂单药可能降低全因死亡(OR 0.70,95%CI 0.49-1.00)。
  • 中等质量证据支持卡维地洛降低首次曲张静脉出血风险(OR 0.21,95%CI 0.08-0.56)。
  • 套扎严重不良事件风险高于非选择性β受体阻滞剂,后者可能是首选初始方案。

核心结论

  • 非选择性β受体阻滞剂单药可能降低肝硬化伴大食管静脉曲张患者的全因死亡和首次曲张静脉出血风险,且严重并发症风险低于套扎,作者认为其可能是食管静脉曲张出血一级预防的首选初始方案。

研究设计与样本

  • 系统评价与网状Meta分析纳入32项随机临床试验,共3362例肝硬化伴大食管静脉曲张且无既往出血史的成人,随访至少12个月。
  • 比较非选择性β受体阻滞剂、硝酸异山梨酯、卡维地洛和曲张静脉套扎单独或联合使用,彼此或与安慰剂对照;采用随机效应网状Meta分析,效应量以比值比(OR)及95%可信区间(CI)表示,并用推荐分级的评估、制定与评价(GRADE)方法评价证据质量。

主要发现

  • 中等质量证据支持非选择性β受体阻滞剂单药降低全因死亡(OR 0.70,95%CI 0.49-1.00),或联合套扎(OR 0.49,95%CI 0.23-1.02)或联合硝酸异山梨酯(OR 0.44,95%CI 0.21-0.93)降低死亡。
  • 中等质量证据支持卡维地洛(OR 0.21,95%CI 0.08-0.56)、套扎单药(OR 0.33,95%CI 0.19-0.55)或套扎联合非选择性β受体阻滞剂(OR 0.34,95%CI 0.14-0.86)用于曲张静脉出血一级预防;低质量证据支持非选择性β受体阻滞剂单药(OR 0.64,95%CI 0.38-1.07)。
  • 套扎相比非选择性β受体阻滞剂严重不良事件风险更高。

临床怎么用

  • 作者认为非选择性β受体阻滞剂可能是肝硬化伴大食管静脉曲张且无出血史患者食管静脉曲张出血一级预防的首选初始方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We performed a systematic review with network meta-analysis (NMA) to compare the efficacy of different approaches in primary prevention of esophageal variceal bleeding and overall survival in patients with cirrhosis with large varices. Thirty-two randomized clinical trials (RCTs) with 3,362 adults with cirrhosis with large esophageal varices and no prior history of bleeding, with a minimum of 12 months of follow-up, were included. Nonselective beta-blockers (NSBB), isosorbide-mononitrate (ISMN), carvedilol, and variceal band ligation (VBL), alone or in combination, were compared with each other or placebo. Primary outcomes were reduction of all-cause mortality and prevention of esophageal variceal bleeding. Random-effects NMA was performed and summary estimates were expressed as odds ratio and 95% confidence intervals (OR; CI). Quality of evidence was critically appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. Moderate quality evidence supports NSBB monotherapy (0.70; 0.49-1.00) or in combination with VBL (0.49; 0.23-1.02) or ISMN (0.44; 0.21-0.93) for decreasing mortality in patients with cirrhosis with large esophageal varices and no prior history of bleeding. Moderate-quality evidence supports carvedilol (0.21; 0.08-0.56) and VBL monotherapy (0.33; 0.19-0.55) or in combination with NSBB (0.34; 0.14-0.86), and low-quality evidence supports NSBB monotherapy (0.64; 0.38-1.07) for primary prevention of variceal bleeding. VBL carries a higher risk of serious adverse events compared with NSBB. Conclusion: NSBB monotherapy may decrease all-cause mortality and the risk of first variceal bleeding in patients with cirrhosis with large esophageal varices. Additionally, NSBB carries a lower risk of serious complications compared with VBL. Therefore, NSBB may be the preferred initial approach for primary prophylaxis of esophageal variceal bleeding.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Sharma M, Singh S, Desai V, et al. Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis. Hepatology. 2019. PMID: 30125369. doi:10.1002/hep.30220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。